Blodgett Wealth Advisors’s AbbVie ABBV Stock Holding History

Blodgett Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$623K	Buy	2,476 +300	+14%	+$64.5K	0.42%	35
2026 Q1	$473K	Sell	2,176 -2,000	-48%	-$444K	0.38%	37
2025 Q4	$954K	Sell	4,176 -50	-1%	-$11.4K	0.67%	25
2025 Q3	$978K	Hold	4,226	–	–	0.67%	25
2025 Q2	$784K	Hold	4,226	–	–	0.61%	27
2025 Q1	$885K	Hold	4,226	–	–	0.75%	23
2024 Q4	$751K	Hold	4,226	–	–	0.59%	28
2024 Q3	$835K	Sell	4,226 -18	-0.4%	-$3.36K	0.7%	24
2024 Q2	$728K	Sell	4,244 -1,000	-19%	-$166K	0.62%	23
2024 Q1	$955K	Hold	5,244	–	–	0.86%	22
2023 Q4	$813K	Hold	5,244	–	–	0.83%	21
2023 Q3	$782K	Sell	5,244 -50	-0.9%	-$7.34K	0.86%	25
2023 Q2	$713K	Sell	5,294 -200	-4%	-$29.3K	0.74%	29
2023 Q1	$876K	Hold	5,494	–	–	1.01%	26
2022 Q4	$888K	Sell	5,494 -200	-4%	-$30.7K	1.08%	26
2022 Q3	$764K	Buy	5,694 +440	+8%	+$63.1K	0.92%	27
2022 Q2	$805K	Sell	5,254 -1,050	-17%	-$160K	0.88%	28
2022 Q1	$1.02M	Buy	6,304 +774	+14%	+$112K	0.85%	29
2021 Q4	$749K	Buy	+5,530	New	+$653K	0.58%	40

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blodgett Wealth Advisors's ABBV Position: Q2 2026 in Review

Blodgett Wealth Advisors increased its AbbVie (ABBV) stake by 14% in Q2 2026, buying an estimated $64.5K and bringing the position to 2,476 shares worth $623K. The position accounts for 0.42% of the portfolio, ranked #35.

Blodgett Wealth Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.02M in Q1 2022. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Blodgett Wealth Advisors held 2,476 shares of AbbVie worth $623K as of Q2 2026.
Blodgett Wealth Advisors bought 300 AbbVie shares in Q2 2026, an estimated $64.5K.
AbbVie made up 0.42% of Blodgett Wealth Advisors's portfolio in Q2 2026, its #35 holding.
Blodgett Wealth Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Blodgett Wealth Advisors's AbbVie position peaked at $1.02M in Q1 2022.
4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Blodgett Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.